| Drug General Information |
| Drug ID |
D0B5OI
|
| Former ID |
DNC003316
|
| Drug Name |
4-Methoxyamphetamine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C10H15NO
|
| Canonical SMILES |
CC(CC1=CC=C(C=C1)OC)N
|
| InChI |
1S/C10H15NO/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3
|
| InChIKey |
NEGYEDYHPHMHGK-UHFFFAOYSA-N
|
| CAS Number |
CAS 23239-32-9
|
| PubChem Compound ID |
|
| PubChem Substance ID |
91153, 841175, 3249416, 4962210, 7962430, 8172362, 10514619, 11407235, 15194941, 29328496, 29535053, 34673826, 46507471, 50004572, 50113081, 56310714, 57311273, 77832186, 103180329, 103934500, 104311633, 117534770, 117854057, 118384425, 125567154, 125810021, 125812893, 126567610, 128689834, 128741831, 131818658, 134224394, 134351252, 134995452, 135022208, 137005596, 139244038, 143441114, 144024467, 160838603, 160964731, 162118404, 162889075, 163403525, 170539116, 172864323, 179680040, 204427290, 223893594, 226612410
|
| Target and Pathway |
| Target(s) |
Alpha-2A adrenergic receptor |
Target Info |
Agonist |
[1]
|
|---|
| Synaptic vesicle amine transporter |
Target Info |
Antagonist |
[1]
|
| Alpha-1D adrenergic receptor |
Target Info |
Agonist |
[1]
|
| Amine oxidase [flavin-containing] B |
Target Info |
Antagonist |
[1]
|
| Amine oxidase [flavin-containing] A |
Target Info |
Antagonist |
[1]
|
| Sodium-dependent dopamine transporter |
Target Info |
Antagonist |
[1]
|
| Alpha-1A adrenergic receptor |
Target Info |
Agonist |
[1]
|
| Sodium-dependent serotonin transporter |
Target Info |
Antagonist |
[1]
|
|
BioCyc Pathway
|
Superpathway of tryptophan utilization
|
|
Tryptophan degradation via tryptamine
|
|
Dopamine degradation
|
|
Putrescine degradation III
|
|
Noradrenaline and adrenaline degradationPWY66-401:Superpathway of tryptophan utilization
|
|
Noradrenaline and adrenaline degradation
|
|
Serotonin degradation
|
|
Superpathway of melatonin degradation
|
|
Melatonin degradation II
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04721:Synaptic vesicle cycle
|
|
Serotonergic synapse
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Alcoholismhsa04020:Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Salivary secretionhsa00260:Glycine, serine and threonine metabolism
|
|
Arginine and proline metabolism
|
|
Histidine metabolism
|
|
Tyrosine metabolism
|
|
Phenylalanine metabolism
|
|
Tryptophan metabolism
|
|
Drug metabolism - cytochrome P450
|
|
Metabolic pathways
|
|
Alcoholismhsa00260:Glycine, serine and threonine metabolism
|
|
Alcoholismhsa04728:Dopaminergic synapse
|
|
AMPK signaling pathway
|
|
Salivary secretionhsa04726:Serotonergic synapse
|
|
NetPath Pathway
|
IL2 Signaling PathwayNetPath_16:IL4 Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
|
5HT1 type receptor mediated signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
5HT3 type receptor mediated signaling pathway
|
|
5HT4 type receptor mediated signaling pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
CCKR signaling map STP00001:Adrenaline and noradrenaline biosynthesis
|
|
5-Hydroxytryptamine degredation
|
|
Dopamine receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
|
Parkinson disease
|
|
Dopamine receptor mediated signaling pathwayP00002:Alpha adrenergic receptor signaling pathwayP04373:5HT1 type receptor mediated signaling pathway
|
|
Pathway Interaction Database
|
Alpha-synuclein signalingalphasynuclein_pathway:Alpha-synuclein signaling
|
|
PathWhiz Pathway
|
Histidine Metabolism
|
|
Tyrosine Metabolism
|
|
Glycine and Serine Metabolism
|
|
Reactome
|
Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-181430:Norepinephrine Neurotransmitter Release Cycle
|
|
Na+/Cl- dependent neurotransmitter transportersR-HSA-390696:Adrenoceptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling eventsR-HSA-181430:Norepinephrine Neurotransmitter Release CycleR-HSA-442660:Na+/Cl- dependent neurotransmitter transportersR-HSA-390696:Adrenoceptors
|
|
G alpha (12/13) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP2855:Dopaminergic Neurogenesis
|
|
Synaptic Vesicle Pathway
|
|
Neurotransmitter Release Cycle
|
|
Nicotine Activity on Dopaminergic NeuronsWP58:Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP465:Tryptophan metabolism
|
|
Dopamine metabolism
|
|
Phase 1 - Functionalization of compoundsWP706:SIDS Susceptibility Pathways
|
|
Biogenic Amine Synthesis
|
|
Oxidative Stress
|
|
Phase 1 - Functionalization of compounds
|
|
Neurotransmitter Clearance In The Synaptic Cleft
|
|
Serotonin Transporter ActivityWP727:Monoamine Transport
|
|
NRF2 pathway
|
|
Dopaminergic Neurogenesis
|
|
Parkinsons Disease Pathway
|
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
|
|
Neurotransmitter Clearance In The Synaptic CleftWP58:Monoamine GPCRs
|
|
Endothelin Pathways
|
|
AMPK SignalingWP727:Monoamine Transport
|
|
SIDS Susceptibility Pathways
|
|
Serotonin Transporter Activity
|
| References |
| REF 1 | Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77. |
|---|
